Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting ACCESSWIRE 20 May 2021, 22:43 GMT+10 SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ('CRD') by Napo Pharmaceuticals, Inc. ('Napo'), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO ®) Annual Meeting, which will be held virtually from June 4-8, 2021. In addition, two CRD-related abstracts from Napo and its collaborators have been accepted for online publication at ASCO.